- Tension: A woman who hated running her entire life loses 40 pounds on semaglutide and spontaneously signs up for a 5K — and nobody, including her, can fully explain why.
- Noise: We’ve been framing GLP-1 drugs as weight loss tools and debating whether they’re “cheating,” but the real story is happening in the brain’s reward circuitry — these drugs appear to be restoring curiosity and motivation, not just suppressing hunger.
- Direct Message: GLP-1 drugs may not be giving people new desires — they may be removing the neurochemical noise that drowned out the ones that were always there.
To learn more about our editorial approach, explore The Direct Message methodology.
Denise Kowalski, 51, a school librarian in Columbus, Ohio, hadn’t run since she was forced to in high school gym class. She hated it then — the burning lungs, the self-consciousness, the way her body felt like it was working against her. For thirty years, running existed in her mind as a punishment, not a pastime. So when she found herself standing in line at a Fleet Feet store last March, buying actual running shoes with actual arch support, she started laughing. The cashier asked what was funny. “I genuinely don’t know why I’m here,” Denise said. “Except that I want to be.”
Six months earlier, her endocrinologist had prescribed semaglutide for her Type 2 diabetes and obesity. She’d lost 40 pounds. That part made sense — GLP-1 receptor agonists suppress appetite, slow gastric emptying, and reduce the hormonal noise that makes every meal feel urgent. What didn’t make sense, at least not to Denise, was the 5K. Nobody told her to sign up. Her doctor didn’t prescribe exercise. Her husband didn’t nudge her. Something in her just — shifted.
Her endocrinologist, when she mentioned it at a follow-up, wasn’t surprised. “The drug didn’t just change your appetite,” he told her. “It changed what your brain finds rewarding.”
That sentence has been rattling around in my head ever since I heard it.
We’ve been telling the story of GLP-1 drugs — Ozempic, Wegovy, Mounjaro, Zepbound — as a weight loss narrative. Pounds lost. Dress sizes dropped. Before-and-after photos that flatten an entire neurochemical revolution into a waistline measurement. But the more interesting story is happening upstream, in the mesolimbic dopamine pathway — the circuit that decides what feels worth doing in the first place.
As we’ve explored before at DMNews, people on these medications are spontaneously starting to exercise, and neuroscientists believe the drugs may be rewiring the brain’s reward system itself. Not suppressing desire — redirecting it. The distinction matters enormously.
A 2023 study published in Molecular Metabolism found that GLP-1 receptors are densely expressed not just in the gut and pancreas, but in the nucleus accumbens and ventral tegmental area — two regions that form the brain’s reward hub. When semaglutide binds to those receptors, it appears to modulate how dopamine is released in response to highly rewarding stimuli. In plain language: the drug turns down the volume on things that used to feel irresistible — food, alcohol, scrolling, compulsive shopping — and in the quiet that follows, other signals start getting through.
Signals like: I wonder what it would feel like to run.
Marcus Chen, 38, a software developer in Portland, Oregon, noticed it with alcohol first. He’d been a reliable two-to-three-beers-a-night guy for a decade. Not alarming. Not a problem, exactly. Just a groove his evenings had worn into. Two months into tirzepatide — prescribed for weight management — he poured a beer one Tuesday, took two sips, and set it down. “It wasn’t willpower,” he told me over email. “It was more like the beer stopped being interesting. Like I’d already seen the movie and didn’t need to watch it again.”
What replaced it startled him. He started building elaborate Lego sets with his seven-year-old daughter. He signed up for a ceramics class. He began reading before bed again — actual books, not Reddit threads. None of this was prescribed. None of it was planned. The void left by dulled compulsions didn’t stay empty. It filled with curiosity.
This pattern is showing up in clinical conversations and online patient communities with striking regularity. Dr. Ania Jastreboff, an obesity medicine specialist at Yale, has noted in interviews with The New York Times that patients report decreased interest not only in food but in a range of compulsive behaviors — gambling, nail-biting, excessive online shopping. The common thread isn’t appetite. It’s the reward signal itself.
There’s a concept in neuroscience sometimes called reward revaluation — the brain’s ability to update what it considers worth pursuing. For most of human history, our reward systems were calibrated to a world of scarcity. High-calorie food was rare and worth chasing. Physical rest was precious and worth protecting. The modern environment inverted those pressures — unlimited calories, unlimited entertainment, unlimited passive comfort — but the ancient circuitry kept running its old program. GLP-1 drugs seem to interrupt that program at the receptor level, giving the brain a chance to recalibrate.
And what people recalibrate toward is fascinating.
Yolanda Reyes, 63, a retired postal worker in San Antonio, started painting watercolors four months into her Wegovy prescription. She’d never painted before. She can’t fully explain the impulse except to say that food used to be the most interesting part of her day, and when it stopped being that, she needed something else that felt alive. Her daughter bought her a beginner’s kit as a joke. Now Yolanda paints every morning for an hour before breakfast.
What strikes me about Yolanda’s story — and Denise’s, and Marcus’s — is how it collides with something psychologists have been saying about aging: the people who decline fastest aren’t the ones with bad genetics; they’re the ones who stopped being curious about anything new. GLP-1 drugs may be, accidentally, chemically restoring curiosity. Not by adding something — by removing the noise that was drowning it out.
This reframes the entire conversation about these medications. The debate has been stuck in a loop: Is it cheating? Is it a shortcut? Is it real change if a drug did it? These questions assume the drug is doing the work for you — that losing weight on semaglutide is like hiring someone to carry you across a finish line. But what if the drug is actually restoring a signal that was always there, just buried under neurochemical static?
Think about it the way you’d think about glasses. Nobody accuses a nearsighted person of “cheating” at reading. The glasses don’t read for you. They correct a signal distortion so your brain can do what it was already designed to do. GLP-1 receptor agonists may be doing something similar for the reward system — correcting a mismatch between ancient circuitry and modern environment so the brain can finally hear its own quieter impulses.
The impulse to move. To make something. To be curious again.
That’s what Denise’s doctor meant. The drug didn’t hand her a new personality. It removed a filter that had been distorting what felt worth doing. For thirty years, her reward system had been hijacked by a food environment designed to be maximally compelling — engineered flavors, caloric density, emotional eating loops reinforced tens of thousands of times. When the volume on that channel dropped, she could finally hear the one underneath it. The one that said: What if you tried running?
It’s worth sitting with how unsettling that is. Because if a medication can shift not just what you eat but what you want — what you find rewarding, interesting, worth getting out of bed for — then we’re talking about something more profound than weight management. We’re talking about pharmacological access to motivation itself. And that raises questions we’re not remotely ready to answer. As a recent piece on the retirement crisis explored, one of the deepest threats to well-being isn’t financial — it’s running out of reasons to leave the house. What happens when a drug can give some of those reasons back?
Denise ran her 5K in April. She finished in 42 minutes, dead last in her age group, and cried at the finish line. Not because she won anything. Because for the first time in decades, she had wanted something that wasn’t food — and she’d followed that wanting all the way to the end.
The drug didn’t carry her across the finish line. It just let her hear the part of herself that wanted to run.
That part had been there the whole time.
Feature image by Alaur Rahman on Pexels
